Decision letter for "MINIMAL RESIDUAL DISEASE (MRD) IN NON‐HODGKIN LYMPHOMAS: INTER‐LABORATORY REPRODUCIBILITY ON MARROW SAMPLES WITH VERY LOW LEVELS OF DISEASE WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK"

2019 ◽  
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
Low Levels ◽  
Minimal Residual

Minimal residual disease (MRD) in non‐Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network

2019 ◽  
Vol 37 (4) ◽  
pp. 368-374 ◽  
Author(s):  
Irene Della Starza ◽  
Marzia Cavalli ◽  
Lucia Anna De Novi ◽  
Elisa Genuardi ◽  
Barbara Mantoan ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
Low Levels ◽  
Interlaboratory Reproducibility ◽  
Minimal Residual

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

Blood ◽  
2000 ◽  
Vol 95 (1) ◽  
pp. 62-66 ◽  
Author(s):  
Andreas Hochhaus ◽  
Andreas Reiter ◽  
Susanne Saußele, Anja Reichert ◽  
Michael Emig ◽  
Jaspal Kaeda ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Chronic Myelogenous Leukemia ◽  
Residual Disease ◽  
Philadelphia Chromosome ◽  
Myelogenous Leukemia ◽  
Maximal Response ◽  
Molecular Evidence ◽  
Molecular Heterogeneity ◽  
Low Levels ◽  
Minimal Residual

Abstract A substantial minority of patients with chronic myelogenous leukemia (CML) achieve a complete response (CR) to treatment with interferon- (IFN), defined as the disappearance of Philadelphia chromosome-positive metaphases. Currently it is unclear how long IFN treatment should be continued for such patients. We used a competitive reverse transcriptase-polymerase chain reaction (RT-PCR) to quantify levels of BCR-ABL transcripts in 297 peripheral blood specimens collected from 54 patients who had achieved CR with IFN. The median duration of observation was 1.9 years (range, 0.3-11.0 years). Total ABL transcripts were quantified as internal control and results were expressed as the ratio BCR-ABL/ABL. All 54 patients had molecular evidence of residual disease, although 3 patients were intermittently PCR negative. The median BCR-ABL/ABL ratio at the time of maximal response for each patient was 0.045% (range, 0%-3.6%). During the period of observation 14 patients relapsed, 11 cytogenetically to chronic phase disease and 3 directly to blastic phase. The median ratio of BCR-ABL/ABL at maximal response was significantly higher in patients who relapsed than in those who remained in CR (0.49% versus 0.021%,P < 0.0001). Our findings show that the level of residual disease falls with time in complete responders to IFN, but molecular evidence of disease is rarely if ever eliminated. The actual level of minimal residual disease correlates with the probability of relapse. We suggest that for patients who reach CR, IFN should be continued at least until relatively low levels of residual leukemia are achieved. (Blood. 2000;95:62-66)

Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

Blood ◽  
2000 ◽  
Vol 95 (1) ◽  
pp. 62-66 ◽  
Author(s):  
Andreas Hochhaus ◽  
Andreas Reiter ◽  
Susanne Saußele, Anja Reichert ◽  
Michael Emig ◽  
Jaspal Kaeda ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Chronic Myelogenous Leukemia ◽  
Residual Disease ◽  
Philadelphia Chromosome ◽  
Myelogenous Leukemia ◽  
Maximal Response ◽  
Molecular Evidence ◽  
Molecular Heterogeneity ◽  
Low Levels ◽  
Minimal Residual

A substantial minority of patients with chronic myelogenous leukemia (CML) achieve a complete response (CR) to treatment with interferon- (IFN), defined as the disappearance of Philadelphia chromosome-positive metaphases. Currently it is unclear how long IFN treatment should be continued for such patients. We used a competitive reverse transcriptase-polymerase chain reaction (RT-PCR) to quantify levels of BCR-ABL transcripts in 297 peripheral blood specimens collected from 54 patients who had achieved CR with IFN. The median duration of observation was 1.9 years (range, 0.3-11.0 years). Total ABL transcripts were quantified as internal control and results were expressed as the ratio BCR-ABL/ABL. All 54 patients had molecular evidence of residual disease, although 3 patients were intermittently PCR negative. The median BCR-ABL/ABL ratio at the time of maximal response for each patient was 0.045% (range, 0%-3.6%). During the period of observation 14 patients relapsed, 11 cytogenetically to chronic phase disease and 3 directly to blastic phase. The median ratio of BCR-ABL/ABL at maximal response was significantly higher in patients who relapsed than in those who remained in CR (0.49% versus 0.021%,P < 0.0001). Our findings show that the level of residual disease falls with time in complete responders to IFN, but molecular evidence of disease is rarely if ever eliminated. The actual level of minimal residual disease correlates with the probability of relapse. We suggest that for patients who reach CR, IFN should be continued at least until relatively low levels of residual leukemia are achieved. (Blood. 2000;95:62-66)

scholarly journals Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia

Blood ◽  
2010 ◽  
Vol 115 (23) ◽  
pp. 4657-4663 ◽  
Author(s):  
Patricia Stow ◽  
Laura Key ◽  
Xiaohua Chen ◽  
Qiulu Pan ◽  
Geoffrey A. Neale ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Minimal Residual Disease ◽  
Clinical Significance ◽  
Induction Therapy ◽  
Residual Disease ◽  
Lymphoblastic Leukemia ◽  
Remission Induction ◽  
Childhood All ◽  
Low Levels ◽  
Minimal Residual

Abstract Minimal residual disease (MRD) at the end of remission-induction therapy predicts relapse in acute lymphoblastic leukemia (ALL). We examined the clinical significance of levels below the usual threshold value for MRD positivity (0.01%) in 455 children with B-lineage ALL, using polymerase chain reaction amplification of antigen-receptor genes capable of detecting at least 1 leukemic cell per 100 000 normal mononucleated cells (0.001%). Of the 455 clinical samples studied on day 46 of therapy, 139 (30.5%) had MRD 0.001% or more with 63 of these (45.3%) showing levels of 0.001% to less than 0.01%, whereas 316 (69.5%) had levels that were either less than 0.001% or undetectable. MRD measurements of 0.001% to less than 0.01% were not significantly related to presenting characteristics but were associated with a poorer leukemia cell clearance on day 19 of remission induction therapy. Patients with this low level of MRD had a 12.7% (± 5.1%; SE) cumulative risk of relapse at 5 years, compared with 5.0% (± 1.5%) for those with lower or undetectable MRD (P < .047). Thus, low levels of MRD (0.001%-< 0.01%) at the end of remission induction therapy have prognostic significance in childhood ALL, suggesting that patients with this finding should be monitored closely for adverse events.

Sign in / Sign up

Export Citation Format

Share Document